Learn More
Purpose: Multiple myeloma is a malignant plasma cell disorder accounting for about 10% of hematological malig-nancies. Despite treatment advances, including hematopoi-etic stem-cell transplantation to facilitate administration of high-dose cytotoxic chemotherapy, the median survival remains approximately 3 years and long-term remissions are rare. Bortezomib(More)
Over the past few years, both the U.S. Food and Drug Administration (FDA) and the pharmaceutical industry have recognized the potential importance of pharmacogenomics and toxicogenomics to drug development. To resolve the uncertainties surrounding the use of microarray technology and the presentation of genomics data for regulatory purposes, several(More)
  • 1